vs
908 Devices Inc.（MASS）与Mirion Technologies, Inc.（MIR）财务数据对比。点击上方公司名可切换其他公司
Mirion Technologies, Inc.的季度营收约是908 Devices Inc.的16.0倍（$277.4M vs $17.4M）。908 Devices Inc.净利率更高（24.0% vs 6.2%，领先17.8%）。908 Devices Inc.同比增速更快（21.2% vs 9.1%）。Mirion Technologies, Inc.自由现金流更多（$63.2M vs $1.3M）。过去两年908 Devices Inc.的营收复合增速更高（53.0% vs 20.0%）
908 Devices Inc.是一家专注于研发、生产高性能便携式质谱分析设备及相关解决方案的科技企业，产品覆盖生命科学研究、生物制药制造、公共安全、法医鉴定、工业过程监测等领域，服务全球科研机构、制药企业及政府部门客户。
Mirion Technologies是全球领先的辐射检测、监测与安全解决方案提供商，核心产品涵盖个人剂量测量系统、辐射成像设备及辐射风险管理软件，服务核电、医疗、国防、工业等多个核心领域，客户遍布北美、欧洲及亚太地区。
MASS vs MIR — 直观对比
营收规模更大
MIR
是对方的16.0倍
$17.4M
营收增速更快
MASS
高出12.1%
9.1%
净利率更高
MASS
高出17.8%
6.2%
自由现金流更多
MIR
多$61.9M
$1.3M
两年增速更快
MASS
近两年复合增速
20.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $17.4M | $277.4M |
| 净利润 | $4.2M | $17.3M |
| 毛利率 | 52.7% | 48.8% |
| 营业利润率 | 17.8% | 9.2% |
| 净利率 | 24.0% | 6.2% |
| 营收同比 | 21.2% | 9.1% |
| 净利润同比 | 121.5% | 15.3% |
| 每股收益（稀释后） | $0.09 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MASSMIR
| Q4 25 | $17.4M | $277.4M | ||
| Q3 25 | $14.0M | $223.1M | ||
| Q2 25 | $13.0M | $222.9M | ||
| Q1 25 | $11.8M | $202.0M | ||
| Q4 24 | $14.3M | $254.3M | ||
| Q3 24 | $14.5M | $206.8M | ||
| Q2 24 | $11.5M | $207.1M | ||
| Q1 24 | $7.4M | $192.6M |
净利润MASSMIR
| Q4 25 | $4.2M | $17.3M | ||
| Q3 25 | $-15.0M | $2.9M | ||
| Q2 25 | $-13.3M | $8.3M | ||
| Q1 25 | $43.6M | $300.0K | ||
| Q4 24 | $-19.4M | $15.0M | ||
| Q3 24 | $-29.3M | $-13.6M | ||
| Q2 24 | $-12.5M | $-11.7M | ||
| Q1 24 | $-10.9M | $-25.8M |
毛利率MASSMIR
| Q4 25 | 52.7% | 48.8% | ||
| Q3 25 | 52.5% | 46.8% | ||
| Q2 25 | 48.9% | 46.0% | ||
| Q1 25 | 47.0% | 47.6% | ||
| Q4 24 | 46.5% | 48.1% | ||
| Q3 24 | 53.6% | 44.9% | ||
| Q2 24 | 53.8% | 47.0% | ||
| Q1 24 | 52.4% | 45.2% |
营业利润率MASSMIR
| Q4 25 | 17.8% | 9.2% | ||
| Q3 25 | -116.6% | 3.3% | ||
| Q2 25 | -116.3% | 4.4% | ||
| Q1 25 | -93.6% | 4.3% | ||
| Q4 24 | -116.8% | 11.4% | ||
| Q3 24 | -168.7% | -0.8% | ||
| Q2 24 | -74.5% | 1.1% | ||
| Q1 24 | -102.5% | -2.5% |
净利率MASSMIR
| Q4 25 | 24.0% | 6.2% | ||
| Q3 25 | -107.0% | 1.3% | ||
| Q2 25 | -102.1% | 3.7% | ||
| Q1 25 | 370.2% | 0.1% | ||
| Q4 24 | -135.6% | 5.9% | ||
| Q3 24 | -201.8% | -6.6% | ||
| Q2 24 | -109.5% | -5.6% | ||
| Q1 24 | -147.1% | -13.4% |
每股收益（稀释后）MASSMIR
| Q4 25 | $0.09 | $0.07 | ||
| Q3 25 | $-0.41 | $0.01 | ||
| Q2 25 | $-0.37 | $0.03 | ||
| Q1 25 | $1.23 | $0.00 | ||
| Q4 24 | $-0.58 | $0.08 | ||
| Q3 24 | $-0.84 | $-0.07 | ||
| Q2 24 | $-0.37 | $-0.06 | ||
| Q1 24 | $-0.33 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $113.0M | $412.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $143.7M | $1.9B |
| 总资产 | $190.1M | $3.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MASSMIR
| Q4 25 | $113.0M | $412.3M | ||
| Q3 25 | $112.1M | $933.2M | ||
| Q2 25 | $118.6M | $262.6M | ||
| Q1 25 | $124.3M | $185.8M | ||
| Q4 24 | $69.6M | $175.2M | ||
| Q3 24 | $71.7M | $133.3M | ||
| Q2 24 | $77.4M | $122.2M | ||
| Q1 24 | $134.2M | $120.2M |
总债务MASSMIR
| Q4 25 | — | — | ||
| Q3 25 | — | $444.8M | ||
| Q2 25 | — | $444.9M | ||
| Q1 25 | — | $686.6M | ||
| Q4 24 | — | $686.4M | ||
| Q3 24 | — | $685.1M | ||
| Q2 24 | — | $684.1M | ||
| Q1 24 | — | $685.5M |
股东权益MASSMIR
| Q4 25 | $143.7M | $1.9B | ||
| Q3 25 | $136.3M | $1.8B | ||
| Q2 25 | $148.8M | $1.5B | ||
| Q1 25 | $159.4M | $1.5B | ||
| Q4 24 | $114.6M | $1.5B | ||
| Q3 24 | $131.0M | $1.5B | ||
| Q2 24 | $156.4M | $1.5B | ||
| Q1 24 | $156.9M | $1.5B |
总资产MASSMIR
| Q4 25 | $190.1M | $3.6B | ||
| Q3 25 | $190.9M | $3.5B | ||
| Q2 25 | $191.7M | $2.7B | ||
| Q1 25 | $196.0M | $2.6B | ||
| Q4 24 | $159.5M | $2.6B | ||
| Q3 24 | $178.3M | $2.7B | ||
| Q2 24 | $208.8M | $2.6B | ||
| Q1 24 | $189.8M | $2.6B |
负债/权益比MASSMIR
| Q4 25 | — | — | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.45× | ||
| Q1 24 | — | 0.47× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3M | $73.0M |
| 自由现金流经营现金流 - 资本支出 | $1.3M | $63.2M |
| 自由现金流率自由现金流/营收 | 7.6% | 22.8% |
| 资本支出强度资本支出/营收 | 0.0% | 3.5% |
| 现金转化率经营现金流/净利润 | 0.32× | 4.22× |
| 过去12个月自由现金流最近4个季度 | $-24.7M | $106.9M |
8季度趋势，按日历期对齐
经营现金流MASSMIR
| Q4 25 | $1.3M | $73.0M | ||
| Q3 25 | $-4.2M | $22.3M | ||
| Q2 25 | $-5.8M | $12.4M | ||
| Q1 25 | $-15.0M | $35.6M | ||
| Q4 24 | $-2.2M | $60.8M | ||
| Q3 24 | $-5.6M | $17.1M | ||
| Q2 24 | $-13.0M | $15.2M | ||
| Q1 24 | $-9.4M | $6.0M |
自由现金流MASSMIR
| Q4 25 | $1.3M | $63.2M | ||
| Q3 25 | $-4.9M | $13.0M | ||
| Q2 25 | $-5.9M | $3.6M | ||
| Q1 25 | $-15.2M | $27.1M | ||
| Q4 24 | $-2.4M | $49.1M | ||
| Q3 24 | $-5.8M | $3.9M | ||
| Q2 24 | $-13.7M | $4.1M | ||
| Q1 24 | $-10.3M | $-6.8M |
自由现金流率MASSMIR
| Q4 25 | 7.6% | 22.8% | ||
| Q3 25 | -34.9% | 5.8% | ||
| Q2 25 | -45.3% | 1.6% | ||
| Q1 25 | -128.9% | 13.4% | ||
| Q4 24 | -17.0% | 19.3% | ||
| Q3 24 | -39.7% | 1.9% | ||
| Q2 24 | -119.4% | 2.0% | ||
| Q1 24 | -138.2% | -3.5% |
资本支出强度MASSMIR
| Q4 25 | 0.0% | 3.5% | ||
| Q3 25 | 4.9% | 4.2% | ||
| Q2 25 | 0.9% | 3.9% | ||
| Q1 25 | 1.4% | 4.2% | ||
| Q4 24 | 1.3% | 4.6% | ||
| Q3 24 | 1.1% | 6.4% | ||
| Q2 24 | 5.6% | 5.4% | ||
| Q1 24 | 12.2% | 6.6% |
现金转化率MASSMIR
| Q4 25 | 0.32× | 4.22× | ||
| Q3 25 | — | 7.69× | ||
| Q2 25 | — | 1.49× | ||
| Q1 25 | -0.34× | 118.67× | ||
| Q4 24 | — | 4.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MASS
| Products | $14.3M | 82% |
| Services | $3.0M | 18% |
MIR
| Transferred Over Time | $96.6M | 35% |
| Services | $65.0M | 23% |
| Cancer Care | $61.8M | 22% |
| Labs And Research | $34.0M | 12% |
| Other Care | $20.7M | 7% |
